Outrun Therapeutics Raises $10M in Seed Financing

Outrun Therapeutics, a Dundee, Scotland, UK-based E3 ligase inhibitor and protein stabilisation developer, has raised $10 million in Seed funding. The funding will be used to expand operations and its R&D sector. The company has developed a proprietary platform that allows for the quantitative assessment of E3 ligase targets, reducing discovery time and improving specificity. Outrun’s approach is a scalable and modular strategy for developing small molecule drugs targeting E3 ligases, particularly inhibitors that stabilise proteins.

Outrun Therapeutics Secures $10 Million in Seed Funding to Develop E3 Ligase Inhibitors

Outrun Therapeutics is a Dundee, Scotland, UK-based E3 ligase inhibitor and protein stabilisation developer. The company has developed a proprietary platform which allows a quantitative assessment of the specificity and selectivity of E3 ligase targets, thereby reducing the discovery time for E3 ligase inhibitors, improving specificity and target binding. Furthermore, it uses engineered protein sensors (EPS) to uncover the detailed biochemistry of E3 ligases, enabling discovery of drugs with potentially superior binding, specificity, and activity. Outrun’s approach is a scalable and modular strategy for developing small molecule drugs targeting E3 ligases, particularly inhibitors that stabilise proteins.

Outrun Therapeutics is a UK-based company developing E3 ligase inhibitors and protein stabilizers.

a year ago

Outrun Therapeutics Secures $10 Million in Seed Funding to Develop E3 Ligase Inhibitors

ProblemHealthcare

Solution

Covered on